Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2025-02-14 am EST			5-day change	1st Jan Change
4,151.00 ^JPY	-0.74%		+0.34%	-0.72%

Feb. 10	All of Donald Trump's tariffs and threatened trade actions	RE
Feb. 07	Bain Capital to Buy Mitsubishi Chemical's Pharma Business for More Than $3 Billion -- Update	DJ

Takeda CEO Weber on Drug Pipeline, Geopolitical Risks

January 13, 2025 at 03:45 pm EST

Takeda Pharmaceutical CEO Christophe Weber discusses the company's drug pipeline and current geopolitical risks with Katie Greifeld at the JPMorgan Health Care Conference in San Francisco.

Bloomberg videos, provided by MT Newswires

Latest news about Takeda Pharmaceutical Company Limited

All of Donald Trump's tariffs and threatened trade actions	Feb. 10	RE
Bain Capital to Buy Mitsubishi Chemical's Pharma Business for More Than $3 Billion -- Update	Feb. 07	DJ
Takeda Pharmaceutical Ends Soticlestat Development After Failed Trials	Jan. 30	MT
Takeda Pharmaceutical Names Next CEO	Jan. 30	MT
Takeda Pharmaceutical Company Limited Announces Chief Executive Officer Changes in June 2026	Jan. 30	CI
Takeda Pharmaceutical Company Limited Announces Retirement of Christophe Weber as President and Representative Director in June 2026	Jan. 30	CI
Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update	Jan. 30	DJ
Takeda Pharmaceutical Names Julie Kim Chief Executive	Jan. 30	MT
Takeda Pharmaceutical Company Limited, Q3 2025 Earnings Call, Jan 30, 2025	Jan. 30
Takeda Pharmaceutical Fiscal Q3 Core Earnings Decline, Revenue Rises	Jan. 30	MT
Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO	Jan. 30	DJ
Japan's Takeda raises full-year forecast after Q3 profit trails forecast	Jan. 30	RE
Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025	Jan. 30	CI
Takeda Provides Update on Soticlestat (TAK-935)	Jan. 30	CI
Takeda Pharmaceutical Company Limited announces an Equity Buyback for 28,500,000 shares, representing 1.8% for ¥100,000 million.	Jan. 29	CI
Takeda Pharmaceutical Company Limited authorizes a Buyback Plan.	Jan. 29	CI
Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment	Jan. 29	MT
Stocks to Watch : Graco, Brown & Brown, Neurocrine Biosciences	Jan. 27	DJ
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment	Jan. 27	DJ
Neurocrine Amends Collaboration with Takeda on Osavampator	Jan. 27	MT
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator	Jan. 27	CI
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO	Jan. 23	RE
Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal	Jan. 21	MT
Smithfield Foods targets up to $10.7 billion valuation in US IPO	Jan. 21	RE
Takeda Canada Says Health Canada Granted Market Authorization for Fruzaqla	Jan. 21	MT

Christophe Weber is a businessperson who has been at the head of 5 different companies and holds the position of President, CEO & Representative Director at Takeda Pharmaceutical Co., Ltd. and President & Chief Executive Officer at Takeda Italia SpA (a subsidiary of Takeda Pharmaceutical Co., Ltd.). Dr. Weber previously held the position of Chairman & Chief Executive Officer at Groupe GlaxoSmithKline SAS, President & Chief Executive Officer of Takeda Pharmaceuticals (Asia Pacific) Pte Ltd., Chief Executive Officer for GlaxoSmithKline Biologicals SA and President & General Manager-Vaccines Division at GlaxoSmithKline Pharmaceuticals SA (Belgium). He received an undergraduate degree from Université Jean Moulin Lyon 3, a doctorate and a graduate degree from the University of Lyon and a graduate degree from Universite Lumiere Lyon 2.

View full profile

Chart Takeda Pharmaceutical Company Limited

Duration

Period

Chart Takeda Pharmaceutical Company Limited

4502: Dynamic Chart

Company Profile

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Employees

49,281

Sector

Pharmaceuticals

Calendar

2025-03-27 - Final dividend

More about the company